Diabetes Mellitus type I affects millions of people around the world and is one of the most common endocrine conditions occurring not only in childhood and adolescence, but is also increasingly diagnosed in adults. The disease is characterized by the destruction of insulin producing cells, consequently causing a depletion of insulin in the body. Since insulin is key for the metabolism of glucose in the body, the inevitable and only currently available treatment is injecting insulin to stay alive.
In order to assure glucose levels stay within a safe range, patients have to regularly monitor these levels. This is either done by finger-prick tests, using Self Monitoring Blood Glucose (SMBG) measuring kits or Continuous Glucose Monitoring (CGM) devices. It is assumed that CGM acceptance will surge globally in the coming years, but certain patients groups and geographical areas will not adopt these devices. This leaves a big part of the market needing to stick with the SMBG which is painful, inconvenient and requires carrying a kit which could hinder patient compliance and affect diabetes management.
Roche has developed Mosquito: an all-in-one solution that combines lancing, sample collection and analysis into easy, one-step testing without the need for separate, lancets and analysers. Mosquito uses cartridges with a very small lancet making it almost painless and drawing a minimal amount of blood. This also reduces damage to the finger which accumulates over time.
The heavily patented design and technical concept has been thought out and heavily patented. Next steps would be to produce the prototype, (clinically) validate it and commercialize the end product.